Rebecca Schweppe, PhD

Professional Titles

• Director, Cancer Biology Graduate Program
• Research Director, Division of Endocrinology, Metabolism, and Diabetes

Recognitions

• Outstanding junior faculty "Rising Stars" award, Department of Medicine (2013)
  Outstanding junior faculty “Rising Stars” award from the Department of Medicine, University of Colorado Anschutz Medical Campus for excellence in research and teaching
• Faculty Sponsor Award, University of Colorado Graduate School (2014)
  Faculty Sponsor Award, University of Colorado Graduate School, Outstanding mentor award
• Dean's Doctoral Mentoring Award, University of Colorado Anschutz Medical Campus Graduate School (2020)
  This award goes to faculty who demonstrate commitment to providing students with a one-on-one, high-quality training experience; maintain high standards of scholarship; and possess personal attributes that make the faculty member an effective role model for other mentors. Faculty are nominated by the doctoral students whom which they mentored for at least one semester and with a significant amount of one-on-one interaction.

Research Interests

The investigation of molecular mechanisms and targeted therapies is critical to help us understand the causes of thyroid cancer, how the tumor grows and spreads, and how we can find new ways to treat advanced disease for which there is currently no cure. The deregulation of protein kinases plays a major role in promoting tumorigenesis in the majority of human cancers, including thyroid cancer, and targeting this deregulated activity has led to major breakthroughs in cancer therapy. The goals of Dr. Rebecca Schweppe’s lab are to understand the regulation and function of deregulated kinase pathways in thyroid cancer in order to develop more effective therapies. We use translational approaches using cell lines derived from thyroid tumors to understand why some tumors are sensitive or resistant to different kinase-directed therapies, with the goal of identifying predictive biomarkers of response, and improving clinical responses. Ultimately, these studies will identify rational and more specific therapies for patients with advanced thyroid cancer. Training Statement: In 2013, I was recognized with the “Rising Stars” outstanding junior faculty award from the Department of Medicine at the University of Colorado for excellence in research and teaching. I am very committed to training PhD and MD scientists, and have been actively involved in graduate student training since 2012. I have held key leadership roles in the Cancer Biology Graduate Program, including Associate Director, Student Advisor, and Chair of Admissions, and in August of 2021, I became Program Director. In 2014, I received an Outstanding Faculty Sponsor award and in 2019, I received the Dean's Doctoral Mentoring Award, both from the University of Colorado Graduate School. In summary, I have demonstrated that I have developed the necessary and innovative tools to study kinase signaling in thyroid cancer, and the necessary skills to mentor students and postdoctoral fellows in cancer research.

Publications

• DIFFERENTIAL SENSITIVITY OF PAPILLARY THYROID CANCER CELLS EXPRESSING THE BRAF V600E MUTATION OR THE RET/PTC1 REARRANGEMENT IN RESPONSE TO MKK1/2 INHIBITION. Rebecca E. Schweppe*, Vidya Pugazhenthi, Anna Kerege and Bryan R. Haugen, University of Colorado at Denver and Health Sciences Center, Aurora, CO 80045.
• Schweppe RE, Cheung TH, Ahn NG. 2006. Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses. J Biol Chem.,281(30):20993-1003.
• Schweppe, RE, Kerege, AA, Pugazhenthi, V and BR Haugen. BRAF V600E Mutation versus RET/PTC Rearrangement are Associated with Differential Responses to MKK1/2 Inhibition in Papillary Thyroid Cancer Cells. International Congress of Endocrinology, June 2-5, 2007, Toronto.
• J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41. Epub 2008 Aug 19. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, Fagin JA, Marlow LA, Copland JA, Smallridge RC, Haugen BR.
• Schweppe, RE, Kerege, AA, Sharma, V, French, JD, and BR Haugen. Focal Adhesion Kinase (FAK) and Src Kinase Signaling in Papillary and Anaplastic Thyroid Cancer. Oral presentation, American Thyroid Association Annual Meeting, October 1-5, 2008, Chicago, IL.
• Schweppe, RE, Klopper, JP, Korch, C, Knauf, JA, Fagin, JA, Marlow, L, Copland, JA, Smallridge, RC, and BR Haugen. DNA Profiling Analysis of Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification. Oral presentation, International Congress of Endocrinology, June 15-18, 2008, San Francisco, CA.
• Loughner, MD, Bauerle, KT, Schweppe, RE, and BR Haugen. Effect of Inhibition of MEK1/2-Dependent NFkB Activity on Thyroid Cancer Cell Proliferation. International Congress of Endocrinology, June 15-18, 2008, San Francisco, CA.
• Old, WM, Shabb, JB, Houel, S, Yen, C-y, Wang, H, Litman, ES, Croy, CH, Meyer-Arendt, K, Couts, KH, Miranda, JG, Brown, RA, Witze, ES, Schweppe, RE, Resing, KA, Ahn, NG. Functional Proteomics Identifies Targets of Phosphorylation by B-Raf Signaling in Melanoma. In press, Molecular Cell.
• Salerno, P, De Falco, V, Tamburrino, A, Nappi, TC, Vecchio, G, Schweppe, RE, Bollag, G, Santoro, M, Salvatore, G. Cytostatic activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells. 2010. J. Clin. Endocrinol. Metab., 95:450-455 [PMID: 19880792]
• Schweppe, RE, Kerege, A, Sharma, V, Poczobutt, JM, Gutierrez-Hartmann, A, Grzywa, RL, and BR Haugen. Distinct Genetic Alterations in the MAPK Pathway Dictate Sensitivity of Thyroid Cancer Cells to MKK1/2 Inhibition. 2009. Thyroid., 19: 825-835 [PMID: 19500021]
• Bauerle KT, Deep G, Schweppe RE, Agarwal R, and BR Haugen. NF kappa B-dependent Growth in an Orthotopic Mouse Model of Advanced Thyroid Cancer Suggests a Role for Interleukin-8 and Angiogenesis. International Congress of Endocrinology, June 19-22, 2010, San Diego, CA.
• Bauerle, K, Schweppe, RE, and BR Haugen. Inhibition of Nuclear Factor-kB Activity Decreases Cancer Cell Invasion and Promotes TNFa-induced Apoptosis in Thyroid Cancer Cells. American Thyroid Association Annual Meeting, September 23-27, 2009, Palm Beach, FL
• Bauerle, KT, Schweppe, RE, and BR Haugen. Inhibition of Nuclear Factor-kB Activity Decreases Cancer Cell Invasion and Promotes TNFa-induced Apoptosis in Thyroid Cancer Cells. Medical Scientist Training Program Annual MD/PhD Student Conference, July 24-26, 2009, Keystone, CO
• Src Signaling in Thyroid Cancer, Novel Mechanisms and Signaling Pathways in Thyroid Cancer Progression, American Thyroid Association Annual Meeting, September 23-27, 2009, Palm Beach, FL
• In Vitro Models of Thyroid Cancer: Strengths & Limitations, International Congress of Endocrinology, June 19-22, 2010, San Diego, CA
• Bauerle, KT, Schweppe, RE, Haugen, BR. Inhibition of NF kappa B Differentially Affects Thyroid Cancer Cell Growth, Apoptosis, and Invasion. 2010. Mol. Cancer., 9:117-130 [PMID: 20492683]
• Salerno, P, De Falco, V, Tamburrino, A, Nappi, TC, Vecchio, G, Schweppe, RE, Bollag, G, Santoro, M, Salvatore, G. Cytostatic activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells. 2010. J. Clin. Endocrinol. Metab., 95:450-455 [PMID: 19880792]
• Chan CM, Lund GS, Sharma, V, Haugen BR, and RE Schweppe. Targeting Src and Focal Adhesion Kinase (FAK) in Thyroid Cancer. International Congress of Endocrinology, June 4-7, 2011, Boston, MA.
• Lund GS, Bauerle KT, Pike LA, Chan CM, Haugen BR, and RE Schweppe. Development of a Novel Model of Distant Metastases in Thyroid Cancer and Assessment of NFkB Signaling on Establishment and Progression of Metastases. International Congress of Endocrinology, June 4-7, 2011, Boston, MA.
• Wood, W, Sharma, V, Bauerle, K, Pike, L, Zhou, Q, Schweppe, R, Haugen, BR. PPAR-gamma Promotes Growth and Invasion of Thyroid Cancer Cells. 2011. PPAR Res., 2011: 171765 [PMID: 22194735].
• Schweppe, RE*, Haugen, BR. Thyroid Targeted KrasG12D /Pten-/- Mice and Their Cell Lines: New Tools to Study Thyroid Cancer Biology. 2011. Thyroid, 21:941-944 [PMID: 21877921]. *Corresponding author
• Chan, CM, Jing, X, Pike, LA, Zhou,Q, Lim, D-J, Lund,GS, Sharma, V, Haugen, BR, and RE Schweppe. Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis. International Congress of Endocrinology, June 23-26, Houston, TX.
• 2. Lund, GS, Pike, LA, Jing, X, Bauerle, KT, Haugen, BR, and RE Schweppe. The Characterization of Tumor Growth and Metastasis of Seven Unique Thyroid Cancer Cell Lines in Two In Vivo Mouse Models of Advanced Thyroid Cancer. International Congress of Endocrinology, June 23-26, Houston, TX.
• 3. Abohashem-Aly, AA, Yu, JA, Schweppe, RE, Ao, L, Meng, X, Haugen, BR, McIntyre Jr., RC, and CD Raeburn. Notch1 Promotes Cellular Proliferation and Invasion of Anaplastic Thyroid Cancer: A New Clinical Target? American Association of Endocrine Surgeons, April 29-May 1, Iowa City, IA.
• Chan, CM, Jing, X, Pike, LA, Zhou,Q, Lim, D-J, Sams, SB, Lund,GA, Sharma, V, Haugen, BR, and RE Schweppe*. Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis. 2012. Clin Cancer Res., 18:3580-3591 [PMID: 22586301]
• Schweppe, RE*. Thyroid Cancer Cell Lines: Critical Models to Study Thyroid Cancer Biology and New Therapeutic Targets. 2012. Frontiers in Cancer Endocrinology, 3:81. [PMID: 22723793]
• Schweppe, RE*. Thyroid Cancer Cell Line Misidentification: An Update. J Clin. Endocrinol. Metab. In press.
• Sharma, V, Qiong, Q, Xia, J, Pike, LA, Kerege, AA, Haugen, BR, and RE Schweppe. Focal Adhesion Kinase (FAK) Activity and Expression Regulate Distinct Pro-tumorigenic Functions in Thyroid Cancer. International Congress of Endocrinology, June 15-18, 2013, San Francisco, CA.
• Dixon, A and RE Schweppe. Targeting Src Through Drug Combination Therapy in Anaplastic and Papillary Thyroid Cancer. Poster presentation, Annual Biomedical Research Conference for Minority Students (ABRCMS), November 7-10, 2012, San Jose, CA.
• Chan, CM, Jing, X, Pike, LA, Zhou,Q, Lim, D-J, Lund,GS, Sharma, V, Haugen, BR, and RE Schweppe. Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis. Oral presentation, International Congress of Endocrinology, June 23-26, 2012, Houston, TX
• Lund, GS, Pike, LA, Jing, X, Bauerle, KT, Haugen, BR, and RE Schweppe. The Characterization of Tumor Growth and Metastasis of Seven Unique Thyroid Cancer Cell Lines in Two In Vivo Mouse Models of Advanced Thyroid Cancer. International Congress of Endocrinology, June 23-26, 2012, Houston, TX
• Schweppe RE. Thyroid cancer cell line misidentification: an update. J Clin Endocrinol Metab. 2013 Mar;98(3):956-7. PubMed PMID: 23472230
• Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb;100(2):E243-52. PubMed PMID: 25427145
• Bauerle KT, Schweppe RE, Lund G, Kotnis G, Deep G, Agarwal R, Pozdeyev N, Wood WM, Haugen BR. Nuclear factor ?B-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab. 2014 Aug;99(8):E1436-44. PubMed PMID: 24758177
• Morrison, JA, Pike, LA, Bauerle, KT, Lund, GS, Kessler, B, Chan, CM, Sams, SB, Haugen, BR, and RE Schweppe*. Animal Models to Study Thyroid Cancer Growth and Metastasis. In Press, Hormones and Cancer.
• Plantinga TS, Heinhuis B, Gerrits D, Netea MG, Joosten LA, Hermus AR, Oyen WJ, Schweppe RE, Haugen BR, Boerman OC, Smit JW, Netea-Maier RT. mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2014 Jul;99(7):E1368-75. PubMed PMID: 24712572
• Chatterji, T, Varkaris, AS, Parikh, NU, Song, JH, Chen, C-J, Schweppe, RE, Alexander, S, Davis, JW, Troncoso, P, Friedl, P, Kuang, J, Lin, S-H, and Gallick GE. Yes-mediated phosphorylation of Focal Adhesion Kinase at Tyrosine 861 Increases Metastatic Potential of Prostate Cancer Cells. In Press, OncoTarget.
• Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget. 2015 Apr 30;6(12):10175-94. PubMed PMID: 25868388
• Pozdeyev N, Yoo M, Mackie R, Schweppe RE, Tan AC, Haugen BR. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. Oncotarget. 2016 Aug 9;7(32):51619-51625. PubMed PMID: 27322211
• Kessler BE, Sharma V, Zhou Q, Jing X, Pike LA, Kerege AA, Sams SB, Schweppe RE. FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes. Mol Cancer Res. 2016 Sep;14(9):869-82. PubMed PMID: 27259715
• Morrison JA, Pike LA, Lund G, Zhou Q, Kessler BE, Bauerle KT, Sams SB, Haugen BR, Schweppe RE. Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer. 2015 Jun;6(2-3):87-99. PubMed PMID: 25800363
• Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE. The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer. Mol Cancer Ther. 2016 Aug;15(8):1952-63. PubMed PMID: 27222538
• Henderson YC, Ahn SH, Ryu J, Chen Y, Williams MD, El-Naggar AK, Gagea M, Schweppe RE, Haugen BR, Lai SY, Clayman GL. Development and characterization of six new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2015 Feb;100(2):E243-52. PubMed PMID: 25427145
• Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE. Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget. 2017 Nov 28;8(61):103014-103031. PubMed PMID: 29262541
• Kiseljak-Vassiliades K, Zhang Y, Bagby S, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe R, Somerset HL, Pitts TM, Leong S, Wierman M. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer. 2018 Jan 25. [Epub ahead of print] PubMed PMID: 29371329
• Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis. 2018 Feb 28;7(2):23. PubMed PMID: 29487290
• Kessler BE, Mishall KM, Kellett MD, Clark EG, Pugazhenthi U, Pozdeyev N, Kim J, Tan AC, Schweppe RE. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene. 2018 Dec 10. [Epub ahead of print] PubMed PMID: 30531837
• Rosenthal MS, Angelos P, Schweppe RE. Research ethics dilemmas in thyroid disease. Curr Opin Endocrinol Diabetes Obes. 2018 Oct;25(5):335-340. PubMed PMID: 30095478
• Oweida A, Phan A, Vancourt B, Robin T, Hararah MK, Bhatia S, Milner D, Lennon S, Pike L, Raben D, Haugen B, Pozdeyev N, Schweppe R, Karam SD. Hypofractionated Radiotherapy Is Superior to Conventional Fractionation in an Orthotopic Model of Anaplastic Thyroid Cancer. Thyroid. 2018 Jun;28(6):739-747. PubMed PMID: 29774792
• Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. PubMed PMID: 29615459
• Beadnell TC, Nassar KW, Rose MM, Clark EG, Danysh BP, Hofmann MC, Pozdeyev N, Schweppe RE. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer. Oncogenesis. 2018 Feb 28;7(2):23. PubMed PMID: 29487290
• Kiseljak-Vassiliades K, Zhang Y, Bagby SM, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe RE, Somerset H, Pitts TM, Leong S, Wierman ME. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer. 2018 Apr;25(4):437-451. PubMed PMID: 29371329
• Schweppe, RE, Korch, C. Challenges and Advances in the Development of Cell Lines and Xenografts. 2018. Advances in Molecular Pathology. 1: 239-251. https://doi.org/10.1016/j.yamp.2018.07.004
• Schweppe, RE, Pozdeyev, N, Pike, LA, Korch, C, Zhou, Q, Sharma, V, Pugazhenthi, U, Sams, SB, Landa-Lopez, I, Knauf, JA, Fagin, JA, and BR Haugen. Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers. Accepted, Mol. Cancer Res.
• Cabinillas, ME, Schweppe, RE, Dadu, R, Cote, GJ, Beadnell, TC, Hofmann, MC. Translational Research and Genomic Driven Trials in Thyroid Cancer. In: Practical Mangement of Thyroid Cancer, Mallick, UK, Harmer, C, Mazzaferri, EL, Kendall-Taylor, P (eds). Springer Second Edition, 2018.
• Landa, I, Pozdeyev, N, Korch, C, Marlow, L, Smallridge, RC, Copland, JA, Henderson, Y, Lai, S, Clayman, G, Onoda, N, Tan, AC, Garcia-Rendueles, MER, Knauf, JA, Haugen, BR, Fagin, JA, Schweppe, RE. Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Accepted, Clin. Cancer Res.
• 2018: Cell line expert for BioCompare, “Reproducibility Issues in Life Sciences Research video: The Importance of Cell Line Authentication”.
• Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clin Cancer Res. 2019 Nov 15;25(22):6883-6884. PubMed PMID: 31732665
• Capes-Davis A, Bairoch A, Barrett T, Burnett EC, Dirks WG, Hall EM, Healy L, Kniss DA, Korch C, Liu Y, Neve RM, Nims RW, Parodi B, Schweppe RE, Storts DR, Tian F. Cell Lines as Biological Models: Practical Steps for More Reliable Research. Chem Res Toxicol. 2019 Sep 16;32(9):1733-1736. PubMed PMID: 31203605
• Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin Cancer Res. 2019 May 15;25(10):3141-3151. PubMed PMID: 30737244
• Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res. 2019 May;17(5):1036-1048. PubMed PMID: 30733375
• Kessler BE, Mishall KM, Kellett MD, Clark EG, Pugazhenthi U, Pozdeyev N, Kim J, Tan AC, Schweppe RE. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene. 2019 Apr;38(14):2565-2579. PubMed PMID: 30531837
• Pozdeyev N, Rose MM, Bowles DW, Schweppe RE. Molecular therapeutics for anaplastic thyroid cancer. Semin Cancer Biol. 2020 Apr;61:23-29. PubMed PMID: 31991166
• Hicks, HM, McKenna, LR, Espinoza, VL, Pozdeyev, N, Pike, LA, Sams, SB, LaBarbera, D, Reigan, P, Raeburn, CD, and RE Schweppe*. Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo. In Press. Molecular Carcinogenesis. *Corresponding Author.
• Pozdeyev, N, Rose, MM, Bowles, DW, and RE Schweppe. Molecular Therapeutics for Anaplastic Thyroid Cancer. Seminars in Cancer Biology
• Cell line expert for the American Type Culture Collection (ATCC) cell line authentication film: Full video
• Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langouët-Astrié C, Amato CM, Chimed TS, Fujita M, Robinson W, Tan AC, Schweppe RE. Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. Mol Cancer Ther. 2021 Oct;20(10):2049-2060. PubMed PMID: 34376578
• Rose MM, Espinoza VL, Hoff KJ, Pike LA, Sharma V, Hofmann MC, Tan AC, Pozdeyev N, Schweppe RE. BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer. Cancers (Basel). 2023 Jan 6;15(2). PubMed PMID: 36672327
• Rose MM, Nassar KW, Sharma V, Schweppe RE. AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition. Med Oncol. 2023 Sep 15;40(10):299. PubMed PMID: 37713162
• Bolf EL, Beadnell TC, Rose MM, D'Alessandro A, Nemkov T, Hansen KC, Schweppe RE. Dasatinib and Trametinib Promote Anti-Tumor Metabolic Activity. Cells. 2023 May 12;12(10). PubMed PMID: 37408209
• Hicks HM, Pozdeyev N, Sams SB, Pugazhenthi U, Bales ES, Hofmann MC, McKenna LR, Schweppe RE. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2. Mol Cancer Res. 2023 Sep 1;21(9):867-880. PubMed PMID: 37219859
• Rose MM, Espinoza VL, Hoff KJ, Pike LA, Sharma V, Hofmann MC, Tan AC, Pozdeyev N, Schweppe RE. BCL2L11 Induction Mediates Sensitivity to Src and MEK1/2 Inhibition in Thyroid Cancer. Cancers (Basel). 2023 Jan 6;15(2). PubMed PMID: 36672327

Professional Memberships

• American Thyroid Association, Full Member
• The National Endocrine Society, Full Member
• American Association for Cancer Research (AACR), Full Member
• International Thyroid Oncology Group (ITOG), Full Member